Non-small cell lung cancer
Conditions
Interventions
18F-TSPF:18F-TSPF
Sponsors
The Affiliated Hospital of Guilin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Voluntarily participates in the clinical study; fully understands and is informed about the study, and personally signs the Informed Consent Form (ICF); willing and able to comply with all study procedures. 2. Aged >= 18 years and = 1.5 x 10^9/L; white blood cell count (WBC) >= 4.0 x 10^9/L; platelet count (PLT) >= 100 x 10^9/L; hemoglobin (Hb) >= 90 g/L; total bilirubin (TBIL) = 30 g/L; international normalized ratio (INR) 1.5 x ULN, creatinine clearance must be >= 50 ml/min (calculated by Cockcroft-Gault formula).
Exclusion criteria
Exclusion criteria: 1. Patients who are preparing for or have previously undergone organ or bone marrow transplantation. 2. Patients with pleural effusion, pericardial effusion, or ascites requiring clinical intervention. 3. Patients known to have or found during screening to have active central nervous system (CNS) metastases and/or carcinomatous meningitis are excluded. However, the following subjects are allowed to enroll: 1) Asymptomatic brain metastases patients (i.e., no progressive CNS symptoms caused by brain metastases, no need for corticosteroids, and lesion size = 450 ms for males and >= 470 ms for females, calculated by Fridericia’s formula) within six months prior to the first imaging. 6. Heart failure classified as NYHA class III–IV or echocardiographic findings showing left ventricular ejection fraction (LVEF) 1.5 mmol/L, or total calcium > 12 mg/dL, or corrected serum calcium above the upper limit of normal [ULN]). 8. Subjects with CTCAE peripheral neuropathy of grade >= 2. 9. Infection with human syphilis or human immunodeficiency virus (HIV). 10. Patients with active pulmonary tuberculosis. 11. Patients with hepatitis B virus infection (positive HBsAg or HBcAb and detectable HBV-DNA) or hepatitis C virus infection (positive HCV antibody and detectable HCV-RNA). Subjects with co-infection of hepatitis B and hepatitis C (positive HBsAg or HBcAb and positive HCV antibody) are also included. 12. Subjects with known active or suspected autoimmune diseases. However, subjects with stable conditions not requiring systemic immunosuppressive therapy are allowed to enroll. 13. Known history of allergy to contrast agents. 14. Pregnant or breastfeeding women. 15. Known history of psychiatric medication abuse or substance abuse. 16. Presence of contraindications to relevant biopsy procedures. 17. In the judgment of the investigator, the subject has other conditions that make them unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax; | — |
Countries
China
Contacts
Public ContactFu Wei
The Affiliated Hospital of Guilin Medical University
Outcome results
None listed